rec_40

Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC Text with EEA relevance · European Union

(40) In order for the sponsor to assess all potentially relevant safety information, the investigator should, as a rule, report to him all serious adverse events.

← rec_39 · All articles · rec_41 →

Source: EUR-Lex (Cellar) · retrieved 2026-11-06 · Text as adopted (Official Journal); later amendments are not incorporated in this text.